This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Exec Summary: The painmanagement market is experiencing exciting growth, driven by several key trends: Increased Demand: Chronic pain prevalence: Chronic pain affects a significant portion of the population, with an aging demographic further increasing demand. The global painmanagement market is expected to reach $3.3
Drugdevelopment: Assessing treatment efficacy and patient adherence. PainManagement Chronic pain: Tracking pain levels, activity levels, and medication use to evaluate treatment effectiveness and identify potential side effects.
Drug discovery: AI-powered tools will accelerate the drugdevelopment process by analyzing vast datasets. Pharmacogenomics: Understanding how genes influence drug response will optimize medication effectiveness and reduce side effects.
Already, this real-world, distributed time of diagnosis approach, has been used to cut down more than four years of estimated drugdevelopment timeline in the instance of PRAX-222, a new therapy for SCN2A, a rare genetic disorder of pediatric epilepsy. Editor’s Note: You can support Lucy’s GoFundme.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content